Zygomatic Approach to Cavernous Sinus Chordoma: 2-Dimensional Operative Video

Abstract

Chordoma is not a benign disease. It grows invasively, has a high rate of local recurrence, metastasizes, and seeds in the surgical field.1 Thus, chordoma should be treated aggressively with radical resection that includes the soft tissue mass and the involved surrounding bone that contains islands of chordoma.2–5 High-dose radiation, commonly by proton beam therapy, is administered after gross total resection for long-term control. About half of chordoma cases occupy the cavernous sinus space and resecting this extension is crucial to obtain radical resection. Fortunately, the cavernous sinus proper extension is the easier part to remove and pre-existing cranial nerves deficit has good chance of recovery. As chordomas originate and are always present extradurally (prior to invading the dura), an extradural access to chordomas is the natural way for radical resection without brain manipulation. The zygomatic approach is key to the middle fossa, cavernous sinus, petrous apex, and infratemporal fossa; it minimizes the depth of field and is highly advantageous in chordoma located mainly lateral to the cavernous carotid artery.6–12 This article demonstrates the advantages of this approach, including the mobilization of the zygomatic arch alleviating temporal lobe retraction, the peeling of the middle fossa dura for exposure of the cavernous sinus, the safe dissection of the trigeminal and oculomotor nerves, and total control of the petrous and cavernous carotid artery. Tumor extensions to the sphenoid sinus, sella, petrous apex, and clivus can be removed. The patient is a 30-yr-old who consented for surgery.

Surgical Approaches to Cavernous Sinus: A Narrative Review of the Literature with Anatomical Drawings.

“…Meningiomas, 11,12 pituitary adenomas, 13 trigeminal schwannoma, 14 and chordomas 15 are just a few of the many CS diseases for which surgery of CS is essential and advantageous. Usually, the need for CS surgery arised in the treatment of several clinical diseases, such as CS syndrome, CS thrombosis, carotidcavernous fistula (CCF) as well as other complications associated with the CSs.…”